Senseonics shares fall after public offering pricing

9 articles · Updated · MarketWatch · May 1

The stock dropped 24% to $5.04 on Friday after touching a 52-week low of $4.96, as the company priced 8 million shares at $5 each.
Senseonics is also selling 8 million pre-funded warrants for just under $5 apiece and expects gross proceeds of about $80 million from the underwritten offering.
Underwriters have a 30-day option to buy up to 2.4 million additional shares, and the deal for the implantable glucose tracker maker is due to close on 4 May.

Could Senseonics’ aggressive expansion and funding plans backfire if patient adoption or revenue growth falls short of projections?

With ongoing losses and rising expenses, is Senseonics at risk of needing further dilutive funding rounds in the near future?

How might the new Eversense 365 and twiist system reshape the competitive landscape for long-term diabetes management?